The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases
Manabu Ono,Seiichi Kobayashi,Hanagama Masakazu,Masatsugu Ishida,Hikari Sato,Koji Okutomo,Yusuke Shirai,Kodai Takahashi,Mitsuhiro Yamada,Naoya Fujino,Shinsuke Yamanda,Masaru Yanai
DOI: https://doi.org/10.1097/md.0000000000038920
IF: 1.6
2024-07-13
Medicine
Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial lung disease (PF-ILD) of unknown origin characterized by excessive and disordered collagen deposition and scarring of the lung parenchyma, leading to deterioration of lung function, worsening respiratory symptoms. [ 1 ] The median survival time is 35 months, and the most common cause of death was acute exacerbation. [ 2 ] Nintedanib is a multi-intracellular tyrosine kinase inhibitor that has anti-fibrotic properties via targeting vascular endothelial growth factor, platelet-derived growth factor, and fibroblast growth factor. Those factors are related with regulations of fibroblast proliferation and migration in the lung, which lead to the pathogenesis of IPF. [ 3 , 4 ] Compared with placebo, nintedanib treatment resulted in a reduced annual decline in forced vital capacity (FVC), which contributed to prolonging the time to the first acute exacerbation and a survival rate in patients with IPF. [ 5 , 6 ] Nintedanib was recommended for the treatment of IPF in the international guideline. [ 7 ] Recently, nintedanib has been approved to use in other progressive fibrosing ILDs such as PF-ILD and systemic sclerosis-associated ILD (SSc-ILD). [ 8 , 9 ] Diarrhea was the most frequent adverse event leading to treatment discontinuation in INPULSIS-ON and the INPULSIS trials. [ 10 ] Several investigators have reported the tolerability of nintedanib in real-world clinical practice. [ 11–13 ] According to studies limited to Japanese patients, the discontinuation rate of nintedanib at a regular dose (300 mg/day) within 6 months was approximately 40%. [ 14 , 15 ] Discontinuations of nintedanib due to adverse events are relatively common in elderly patients (26.4%), even in younger patients (16.0%). [ 16 ] Several studies reported that older age, low body weight, body mass index (BMI) were possible risk factors for discontinuation of nintedanib. [ 17 , 18 ] We hypothesized these factors may be associated with sarcopenia, which is defined as age-related loss of skeletal muscle mass plus loss of muscle strength and/or reduced physical performance. The dorsal muscle group area at the T12 vertebral level (T12DMA) is a novel indicator to evaluate skeletal muscle using routine chest computed tomography (CT) images. The relationship between the T12DMA and the discontinuation of nintedanib remains unclear. Here we investigated predictive factors for the tolerability of nintedanib, including T12DMA, in patients with IPF and other progressive fibrosing ILDs.
medicine, general & internal